This invention concerns the compounds of formula
##STR1##
the pharmaceutically acceptable acid addition salts and the stereochemically
isomeric forms thereof, wherein R1 and R2 are each independently
selected from hydrogen; hydroxy; amino; optionally substituted C1-6alkyl;
C1-6alkyloxy; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl;
Ar1; mono- or di(C1-6alkyl)amino; mono- or di(C1-6alkyl)aminocarbonyl;
dihydro-2(3H)-furanone; or R1 and R2 taken together may form
pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-6alkyl)amino-C1-4alkylidene;
R3 is hydrogen, Ar1, C1-6alkylcarbonyl, C1-6alkyl,
C1-6alkyloxycarbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl;
and R4, R5, R6, R7 and R8 are
each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy,
cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is optionally
substituted C1-10alkyl; C3-10alkenyl; C3-10alkynyl;
C3-7cycloalkyl; Ar1 is optionally substituted phenyl; for
the manufacture of a medicine for the treatment of subjects suffering from HIV
(Human Immunodeficiency Virus) infection. It further relates to new compounds being
a subgroup of the compounds of formula (I), their preparation and compositions
comprising them.
